Office of National Drug Control Policy

The Office of National Drug Control Policy is presented as a federal actor with the power to shape whether drug courts make medication-assisted treatment (MAT) available, but also as an office whose commitment was weakened by budget proposals and uncertain leadership. Its record in the book is marked by a sharp contrast: in 2016, it announced a funding condition supporting access to MAT, while the following administration proposed a major reduction in the office’s budget and left its leadership unsettled. The contrast makes the office a measure of how federal policy signals can advance treatment even as the wider political response remains unstable.

Treatment Policy and Drug Courts

In 2016, after a Kentucky appeals court required its drug courts to allow MAT, the Office of National Drug Control Policy announced that it would deny funding to drug courts that cut off access to it. The decision placed federal funding behind a specific treatment principle: people in drug courts should not be required to forgo medication as a condition of participation. In the book’s account, the announcement challenged a persistent divide between public-health professionals who supported MAT and many Virginia drug-court prosecutors and judges who prohibited it.

That dispute mattered because drug courts occupy an unusual position between care and punishment. They monitor participants closely, coordinate prosecutors, defense attorneys, judges, and mental-health advocates, and can impose swift consequences for failed drug tests or new offenses. Most courts drop charges when participants complete their programs; graduates are less likely to return to crime or drug use than people on regular probation. The book thus presents these courts as both an opportunity to connect people to treatment and a setting where restrictions on medication can determine what treatment is actually available. The office’s 2016 funding announcement used a federal resource to oppose one such restriction.

The policy was significant in a treatment landscape where MAT faced resistance beyond courtrooms. Some members of twelve-step groups regarded people taking Suboxone as unable to participate fully, while public-health advocates argued that medication could be an essential part of treatment. Against this background, the office’s announcement represented a concrete federal position, not merely a general endorsement of recovery services. It attached a funding consequence to a court’s decision to deny access. The account does not describe that position as resolving the conflict: the disagreement remained a major barrier to reducing overdose deaths.

Budget Proposals and Administrative Uncertainty

The office’s treatment-oriented signal was followed by a different kind of federal signal. Two months after the Trump administration took office, it proposed reducing the White House drug czar’s office budget by $364 million, despite the president’s campaign pledge to address the opioid crisis. The same administration backed health-care changes that, in the book’s assessment, would have put vulnerable drug users at risk. Following public backlash, the administration rolled back the proposed reductions to comparatively modest trims. The sequence was therefore neither a complete withdrawal of support nor a sustained expansion: a sweeping proposal was narrowed after opposition.

Budget was only one sign of uncertainty. More than a year after the inauguration, the office still lacked a permanent director. The book describes the administration as more focused on law enforcement than public-health strategies, while a comprehensive list of recommendations from its own presidential commission remained unfinished or unaddressed. These details set the office’s formal policy role against the unevenness of its surrounding administration: the federal government could announce a treatment condition for drug-court funding, yet its wider response left leadership and implementation in question.

In February 2018, the president signaled Jim Carroll’s nomination to lead the office, after Carroll had disappointed him as deputy chief of staff. The nomination indicated a possible change in leadership, not a settled appointment. Meanwhile, White House counselor Kellyanne Conway had become the president’s point person on opioids. The account describes drug-policy professionals as being sidelined while political staff took on the crisis, which was then claiming about 175 lives a day. In this setting, the director vacancy was more than an administrative detail: it formed part of a broader picture of a response whose responsibility and direction remained unsettled.

Federal Signals and Local Treatment Barriers

The office’s position on drug-court funding addressed one policy barrier, but the book’s local scenes show how far an announcement could be from treatment in practice. In Roanoke, people seeking help encountered shortages of MAT providers, detox services, and treatment beds. Efforts to create a smoother transfer from emergency care into MAT and counseling were hindered by bureaucratic, financial, and legal obstacles. Even after a local initiative attracted people asking for help, none of the first twenty-two had entered residential treatment in its first month, and only a handful had obtained outpatient MAT.

These accounts do not establish that the office directed or caused the local shortages. Their significance is the contrast they provide: a federal funding policy could challenge courts that barred medication, while access on the ground still depended on scarce providers, available beds, and a successful handoff between institutions. The office’s intervention addressed a rule; it could not, by itself, create the treatment capacity that made the rule meaningful to people seeking care.

Narrative Significance

The Office of National Drug Control Policy occupies a point of tension in the book’s account of addiction policy. Its 2016 announcement shows that federal leverage could be used to defend MAT against categorical bans in drug courts. The later budget proposal, partial retreat, prolonged director vacancy, and unfinished recommendations show how fragile such a direction could be within an administration that the book characterizes as favoring law enforcement over public health.

That tension echoes the book’s wider criticism of treating addiction primarily as a criminal-justice problem. Drug courts combine monitoring and punishment with treatment coordination; the office’s funding condition supported one route toward medication within that mixed system. Yet local treatment shortages and continuing resistance to MAT reveal that changing a policy signal does not automatically change the institutions or resources people encounter. The office therefore represents both the possibility and the limits of federal influence: it could make access to treatment a condition of support, but the broader response described in the book lacked the consistent leadership and practical capacity needed to make treatment reliably available.